Overview

Comparing the Combination of Trastuzumab and Regorafenib With Regorafenib Monotherapy for Advanced Hepatocellular Carcinoma After First-line Treatment

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

At present, there is no standard treatment plan for hepatocellular carcinoma after the progress of first-line target immunotherapy. Based on the above research background, we believe that the combination of PD-1 inhibitors and multi-target inhibitors is a promising treatment option for second-line liver cancer. Our study aims to explore the efficacy and safety of trastuzumab monoclonal antibody combined with regorafenib compared to regorafenib monotherapy for second-line treatment of advanced hepatocellular carcinoma after previous target immunotherapy progression.

Phase:

PHASE2

Details

Lead Sponsor:

Tianjin Medical University Cancer Institute and Hospital

Treatments:

regorafenib
tislelizumab